Albumin Administration to Increase B-Cell Receptor Density
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for defective B-cell function in patients with systemic inflammatory response syndrome and related conditions, such as sepsis and cirrhosis, are inadequate, leading to immunosuppression and increased susceptibility to infections and cancer progression.
Innovation Solution
Administration of human albumin to selectively activate B-cell function, increasing B-cell Receptor density in naïve, transitional, and marginal B-cells, thereby enhancing the adaptive immune response without affecting T-cell compartments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for defective B-cell function, then patient conditions are managed, but immune suppression persists and susceptibility to infections increases
Solution Approach 1:
The patent applies parameter changes by administering albumin at specific doses (e.g., 1-10 g/kg body weight) to modulate B-cell function. The albumin concentration and dosage are carefully controlled to achieve activation of B-cell receptors without causing excessive immune response, thereby resolving the contradiction between improving B-cell function and avoiding harmful immunosuppression effects.
Solution Approach 2:
Albumin serves as an intermediary substance that mediates the immune response. It binds to B-cell receptors and triggers signaling pathways that enhance B-cell activation and antibody production, while simultaneously regulating the overall immune system to prevent harmful immunosuppression and infection susceptibility.
2Productivity
If albumin is administered to increase B-cell Receptor density, then adaptive immune response is enhanced, but system complexity of immune regulation increases
Solution Approach 1:
Albumin exhibits multi-functionality in the immune system. It not only increases B-cell Receptor density and enhances adaptive immune response but also serves as a plasma expander, acute phase reactant, and regulator of inflammation. This universal substance can improve multiple immune parameters simultaneously without requiring complex multi-drug regimens, thereby reducing system complexity while increasing productivity.
Solution Approach 2:
The albumin administration system operates in a self-regulating manner. The albumin molecules naturally bind to B-cell receptors and trigger activation pathways without requiring external intervention or complex control mechanisms. The immune system itself regulates the response based on the albumin concentration and patient condition, simplifying the overall regulation system while maintaining high adaptive immune response productivity.
Data Source
AI summary
Use of albumin for the treatment of defective B-cell functionThe present invention refers to a composition comprising human albumin for regulating B-cell function in a patient suffering from systemic inflammatory response syndrome, in which the albumin is administered to the patient in a dose sufficient to increase B-cell Receptor density in a B-cell population.